Cumberland Pharmaceuticals
As of the edition of 20 October 2026, Cumberland Pharmaceuticals runs 6 drugs, 5 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methotrexate | none listed | 2 |
| Ibuprofen | none listed | 11 |
| Acetylcysteine | none listed | 0 |
| Conivaptan | none listed | 0 |
| Telavancin | Ends 2027 (patent) | 0 |
A route B row is one company at one target.
Where its trials are
- Infections: 7 trials led
- Skin and connective tissue: 5 trials led
- Lungs and airways: 4 trials led